Timothy Rolph Akero Therapeutics, Inc. (AKRO) insider trading activity

AKRO Quotes by TradingView

Timothy Rolph is Chief Scientific Officer of Akero Therapeutics, Inc.. Currently has a direct ownership of 169,721 shares of AKRO, which is worth approximately $6.39 Million. The most recent transaction as insider was on Jun 13, 2023, when has been sold 509 shares (Common Stock) at a price of $55.16 per share, resulting in proceeds of $28,076. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 170K
0.3% 3M change
7.03% 12M change
Total Value Held $6.39 Million

Timothy Rolph Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 13 2023
SELL
Open market or private sale
$28,076 $55.16 p/Share
509 Reduced 0.27%
189,420 Common Stock
Mar 10 2023
SELL
Payment of exercise price or tax liability
$26,212 $43.47 p/Share
603 Reduced 0.32%
189,929 Common Stock
Dec 29 2022
SELL
Open market or private sale
$1,035,506 $50.97 p/Share
20,316 Reduced 9.64%
190,532 Common Stock
Dec 29 2022
BUY
Exercise of conversion of derivative security
$221,583 $28.35 p/Share
7,816 Added 3.57%
210,848 Common Stock
Dec 28 2022
SELL
Open market or private sale
$85,000 $50.0 p/Share
1,700 Reduced 0.83%
203,032 Common Stock
Dec 28 2022
BUY
Exercise of conversion of derivative security
$48,195 $28.35 p/Share
1,700 Added 0.82%
204,732 Common Stock
Dec 09 2022
BUY
Grant, award, or other acquisition
-
19,195 Added 8.64%
203,032 Common Stock
Nov 16 2022
SELL
Open market or private sale
$180,575 $45.75 p/Share
3,947 Reduced 2.1%
183,837 Common Stock
Nov 15 2022
SELL
Open market or private sale
$141,335 $45.04 p/Share
3,138 Reduced 1.64%
187,784 Common Stock
Oct 26 2022
SELL
Open market or private sale
$214,433 $45.03 p/Share
4,762 Reduced 2.43%
190,922 Common Stock
Oct 25 2022
SELL
Open market or private sale
$480,344 $45.09 p/Share
10,653 Reduced 5.16%
195,684 Common Stock
Oct 25 2022
BUY
Exercise of conversion of derivative security
$173,600 $17.36 p/Share
10,000 Added 4.62%
206,337 Common Stock
Oct 06 2022
SELL
Open market or private sale
$884,025 $39.29 p/Share
22,500 Reduced 10.77%
186,337 Common Stock
Oct 06 2022
BUY
Exercise of conversion of derivative security
$210,900 $21.09 p/Share
10,000 Added 4.57%
208,837 Common Stock
Sep 30 2022
SELL
Open market or private sale
$1,472,400 $32.72 p/Share
45,000 Reduced 18.45%
198,837 Common Stock
Sep 30 2022
BUY
Exercise of conversion of derivative security
$274,600 $13.73 p/Share
20,000 Added 7.58%
243,837 Common Stock
Sep 13 2022
SELL
Open market or private sale
$656,550 $29.18 p/Share
22,500 Reduced 9.13%
223,837 Common Stock
Jun 30 2022
BUY
Grant, award, or other acquisition
$9,251 $8.03 p/Share
1,152 Added 0.47%
246,337 Common Stock
Jun 30 2021
BUY
Grant, award, or other acquisition
$21,238 $21.09 p/Share
1,007 Added 0.41%
245,185 Common Stock
Jun 30 2020
BUY
Grant, award, or other acquisition
$21,252 $17.07 p/Share
1,245 Added 0.51%
244,178 Common Stock
TR

Timothy Rolph

Chief Scientific Officer
South San Francisco, CA

Track Institutional and Insider Activities on AKRO

Follow Akero Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AKRO shares.

Notify only if

Insider Trading

Get notified when an Akero Therapeutics, Inc. insider buys or sells AKRO shares.

Notify only if

News

Receive news related to Akero Therapeutics, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on AKRO